Related Experiment Videos
A global safety evaluation of etodolac
1University of Münster, Federal Republic of Germany.
Clinical Rheumatology
|March 1, 1989
Summary
Etodolac demonstrates a consistently excellent safety profile, with low rates of patient complaints and laboratory abnormalities. Recent studies confirm its safety, even in older patients, with most events occurring early in treatment.
Area of Science:
- Pharmacology
- Clinical Safety
Background:
- Etodolac is a nonsteroidal anti-inflammatory drug (NSAID).
- Previous data indicated an excellent safety profile for etodolac.
Purpose of the Study:
- To compare recent clinical trial and clinical practice data with historical safety data for etodolac.
- To further evaluate the safety profile of etodolac.
Main Methods:
- Comparative analysis of safety data from recent clinical trials.
- Evaluation of safety data from a clinical practice study.
- Assessment of patient complaints and laboratory abnormalities.
Main Results:
- The overall incidence of patient complaints and laboratory abnormalities remained low.
- No increase in side effects was observed with increasing patient age.
- In the clinical practice study, 60% of adverse events occurred within the first 10 weeks of therapy.
Conclusions:
- Recent data reinforce the excellent safety profile of etodolac.
- Etodolac exhibits a favorable safety margin across different patient demographics.
- Early monitoring may be beneficial for identifying potential adverse events.